about
CD133, Selectively Targeting the Root of CancerTargeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem CellsIL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer.Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linkerTherapy implications of the role of interleukin-2 in cancer.The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.CD56 in the Immune System: More Than a Marker for Cytotoxicity?CD56bright NK cells exhibit potent antitumor responses following IL-15 priming.IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced FunctionTetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker.IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients.Effects of a Phosphoinositide-3-Kinase Inhibitor on Anaplastic Thyroid Cancer Stem CellsAssociation between Recipient IL-15 Genetic Variant and the Prognosis of HBV-Related Hepatocellular Carcinoma after Liver Transplantation.Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.IL-2 and Beyond in Cancer Immunotherapy.Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
P2860
Q28066353-876C0FF7-F519-453A-BFE7-44E73ACBD3F7Q28078154-3679834B-1F76-49A6-B2D0-5A67BA0ABD74Q36335722-BCC05362-AEBB-41EA-A54A-4124289E4D09Q36539682-E222E685-2ECF-4CD8-8866-E41C22EDA143Q37658381-6F2A1F4D-3FA3-418B-AFC4-5B974F3CDCDEQ38772382-A9B5B91F-224E-40B3-91C4-91F9AD807010Q38805382-1D92A1CB-31D8-4B11-8C85-7CDE65C485A5Q38831202-BE0F25F8-C4DE-4537-80A5-6522D3103C6EQ40101148-CF0C30F1-AEE4-49AD-9A67-F13A1DFFCF28Q41991684-67ADD07C-4845-42FB-8DAC-F31AAF27CBB2Q42134875-F73F3F9D-AC81-407C-8B2A-EC0CA8ACD368Q42221543-C8F75FDF-FD84-4E14-B950-FDC0B383803BQ45765887-6AAAEA39-71D2-48A2-853C-E9EBDFD86DB3Q47107349-599EE970-06F0-41BA-97BE-59FB15A6C913Q47160952-1D11CDD0-2C0E-49BC-B578-3BDFDC828552Q47277628-41BE76E8-1714-477A-931E-318C26FCA293Q49878390-77A4AE12-1994-4C2F-844D-4063DF1FDF6DQ50004232-7B40AD40-AC7C-4DA2-B057-E7B5665BDF9AQ50034163-F8266FD8-FCFE-441E-AFEF-8EC014881108Q50992976-62BAF009-2CB4-4525-8908-6F157500F2FC
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Interleukin-15 in the treatment of cancer.
@en
type
label
Interleukin-15 in the treatment of cancer.
@en
prefLabel
Interleukin-15 in the treatment of cancer.
@en
P2860
P1476
Interleukin-15 in the treatment of cancer.
@en
P2093
Thomas A Waldmann
P2860
P304
P356
10.1586/1744666X.2014.973856
P577
2014-10-31T00:00:00Z